1466565-67-2Relevant academic research and scientific papers
Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate
Evans, Catherine A.,Liu, Tao,Lescarbeau, André,Nair, Somarajan J.,Grenier, Louis,Pradeilles, Johan A.,Glenadel, Quentin,Tibbitts, Thomas,Rowley, Ann M.,Dinitto, Jonathan P.,Brophy, Erin E.,O'Hearn, Erin L.,Ali, Janid A.,Winkler, David G.,Goldstein, Stanley I.,O'Hearn, Patrick,Martin, Christian M.,Hoyt, Jennifer G.,Soglia, John R.,Cheung, Culver,Pink, Melissa M.,Proctor, Jennifer L.,Palombella, Vito J.,Tremblay, Martin R.,Castro, Alfredo C.
supporting information, p. 862 - 867 (2016/10/06)
Optimization of isoquinolinone PI3K inhibitors led to the discovery of a potent inhibitor of PI3K-γ (26 or IPI-549) with >100-fold selectivity over other lipid and protein kinases. IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration in vivo and is currently in Phase 1 clinical evaluation in subjects with advanced solid tumors.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
, (2013/10/22)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
